B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
NRXP
NRXCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The primary-source picture improved modestly: Q1 revenue of about $1.1 million from Dura, net loss narrowed to about $1.4 million from $5.5 million a year earlier, and post-quarter ATM proceeds added roughly $7.0 million of cash support. If KETAFREE reaches a Summer 2026 approval path and NRX-100 is filed in Q2 2026, the stock could re-rate from a low base.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.0.
What can break
HOPE and Dura integration add execution risk because the current revenue base is still small and depends on successful clinic expansion and operational scaling. [#10-Q-2026-05-15]
Momentum
37
Value
41
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $6.00 · Bear $1.50Analysis 2026-05-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $34.67
Why
Momentum37 · Δ7d +18.7
Value41 · Δ7d 0.0
Sentiment68 · Δ7d +5.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.0.
Contradictions & invalidation
- • HOPE and Dura integration add execution risk because the current revenue base is still small and depends on successful clinic expansion and operational scaling. [#10-Q-2026-05-15]
- • Regulatory timing remains management-described: KETAFREE review is targeted for Summer 2026 and NRX-100 filing is targeted for Q2 2026, but neither is yet a completed approval milestone. [#10-Q-2026-05-15]
- • This is still a low-coverage, financing-sensitive biotech.
Catalyst clock
2026-05-18
May 18, 2026 earnings release and corporate update should resolve the timing mismatch in this follow-up run
Lead driver: Sentiment · See AI snapshot
Momentum
37
9% active weight
Current posture
7d trendImproving
Δ7d
+18.7
Δ21d
+22.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
68
62% active weight
Current posture
7d trendImproving
Δ7d
+5.0
Δ21d
+0.9
Why this grade
Composite grade C. Momentum 36.5 / Value 41.2 / Sentiment 67.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-16. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$148.5M
Beta
1.92
Shares Out
43.3M
P/E (TTM) · Derived
-2.6
P/S (TTM)
279.82
P/FCF (TTM) · Derived
-5.36
Rev YoY
-
EPS YoY
-55.2%
Gross Margin
+32.7%
Op Margin
-588.1%
Net Debt
-$7.17M
Current Ratio
0.86
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data